

Richard J Lee

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2370415/publications.pdf>

Version: 2024-02-01

52
papers

2,798
citations

304368

22
h-index

264894

42
g-index

52
all docs

52
docs citations

52
times ranked

5483
citing authors

#	ARTICLE	IF	CITATIONS
1	RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance. <i>Science</i> , 2015, 349, 1351-1356.	6.0	614
2	Prostate Cancer, Version 1.2016. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 19-30.	2.3	544
3	Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience. <i>European Urology</i> , 2017, 71, 952-960.	0.9	253
4	Quality of Life in Long-term Survivors of Muscle-Invasive Bladder Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 1028-1036.	0.4	122
5	Circulating tumour cells—monitoring treatment response in prostate cancer. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 401-412.	12.5	110
6	An RNA-Based Digital Circulating Tumor Cell Signature Is Predictive of Drug Response and Early Dissemination in Prostate Cancer. <i>Cancer Discovery</i> , 2018, 8, 288-303.	7.7	107
7	Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting. <i>European Urology</i> , 2018, 73, 715-723.	0.9	105
8	Expression of β -globin by cancer cells promotes cell survival during blood-borne dissemination. <i>Nature Communications</i> , 2017, 8, 14344.	5.8	96
9	Treatment and prevention of bone complications from prostate cancer. <i>Bone</i> , 2011, 48, 88-95.	1.4	79
10	Glutaminase and poly(ADP-ribose) polymerase inhibitors suppress pyrimidine synthesis and VHL-deficient renal cancers. <i>Journal of Clinical Investigation</i> , 2017, 127, 1631-1645.	3.9	72
11	A Dose-Ranging Study of Cabozantinib in Men with Castration-Resistant Prostate Cancer and Bone Metastases. <i>Clinical Cancer Research</i> , 2013, 19, 3088-3094.	3.2	69
12	Prospective Comprehensive Genomic Profiling of Primary and Metastatic Prostate Tumors. <i>JCO Precision Oncology</i> , 2019, 3, 1-23.	1.5	63
13	Disparities in Cancer Care and the Asian American Population. <i>Oncologist</i> , 2021, 26, 453-460.	1.9	59
14	CB-839, a glutaminase inhibitor, in combination with cabozantinib in patients with clear cell and papillary metastatic renal cell cancer (mRCC): Results of a phase I study. <i>Journal of Clinical Oncology</i> , 2019, 37, 549-549.	0.8	44
15	Prostate cancer in transgender women. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 518-525.	0.8	41
16	The induction of the p53 tumor suppressor protein bridges the apoptotic and autophagic signaling pathways to regulate cell death in prostate cancer cells. <i>Oncotarget</i> , 2014, 5, 10678-10691.	0.8	36
17	Current Status of MRI and PET in the NCCN Guidelines for Prostate Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 506-513.	2.3	33
18	Targeting MET and Vascular Endothelial Growth Factor Receptor Signaling in Castration-Resistant Prostate Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2013, 19, 90-98.	1.0	32

#	ARTICLE	IF	CITATIONS
19	Prognostic risk stratification derived from individual patient level data for men with advanced penile squamous cell carcinoma receiving first-line systemic therapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 501-508.	0.8	31
20	CANTATA: Primary analysis of a global, randomized, placebo (Pbo)-controlled, double-blind trial of telaglenastat (CB-839) + cabozantinib versus Pbo + cabozantinib in advanced/metastatic renal cell carcinoma (mRCC) patients (pts) who progressed on immune checkpoint inhibitor (ICI) or anti-angiogenic therapies.. <i>Journal of Clinical Oncology</i> , 2021, 39, 4501-4501.	0.8	30
21	Concurrent Chemoradiotherapy for Men With Locally Advanced Penile Squamous Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 440-446.	0.9	29
22	Branched Chain RNA <i>in Situ</i> Hybridization for Androgen Receptor Splice Variant AR-V7 as a Prognostic Biomarker for Metastatic Castration-Sensitive Prostate Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 363-369.	3.2	23
23	Telaglenastat Plus Cabozantinib or Everolimus for Advanced or Metastatic Renal Cell Carcinoma: An Open-Label Phase I Trial. <i>Clinical Cancer Research</i> , 2022, 28, 1540-1548.	3.2	21
24	Contemporary Therapeutic Approaches Targeting Bone Complications in Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2010, 8, 29-36.	0.9	18
25	Viral integration in BK polyomavirus-associated urothelial carcinoma in renal transplant recipients: multistage carcinogenesis revealed by next-generation virome capture sequencing. <i>Oncogene</i> , 2020, 39, 5734-5742.	2.6	17
26	Phase 1 study of glutaminase (GLS) inhibitor CB-839 combined with either everolimus (E) or cabozantinib (Cabo) in patients (pts) with clear cell (cc) and papillary (pap) metastatic renal cell cancer (mRCC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 603-603.	0.8	17
27	Investigator-sponsored trial of efficacy and tolerability of cabozantinib (cabo) at lower dose: A dose-finding study in men with castration-resistant prostate cancer (CRPC) and bone metastases.. <i>Journal of Clinical Oncology</i> , 2012, 30, 4566-4566.	0.8	17
28	Characterization of the effects of defined, multidimensional culture conditions on conditionally reprogrammed primary human prostate cells. <i>Oncotarget</i> , 2018, 9, 2193-2207.	0.8	16
29	Effect of PD-L1 testing on the cost-effectiveness and budget impact of pembrolizumab for advanced urothelial carcinoma of the bladder in the United States. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 180.e11-180.e18.	0.8	12
30	Durvalumab as neoadjuvant therapy for muscle-invasive bladder cancer: Preliminary results from the Bladder Cancer Signal Seeking Trial (BLASST)-2.. <i>Journal of Clinical Oncology</i> , 2020, 38, 507-507.	0.8	12
31	Cell-free and circulating tumor cell-based biomarkers in men with metastatic prostate cancer: Tools for real-time precision medicine?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 490-501.	0.8	11
32	Quality of life in long-term survivors of muscle-invasive bladder cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 319-319.	0.8	10
33	Predicting new drug indications for prostate cancer: The integration of an <i>in silico</i> proteochemometric network pharmacology platform with patient-derived primary prostate cells. <i>Prostate</i> , 2020, 80, 1233-1243.	1.2	9
34	Charting a Path Towards Asian American Cancer Health Equity: A Way Forward. <i>Journal of the National Cancer Institute</i> , 2022, 114, 792-799.	3.0	9
35	Genome-wide profiling of BK polyomavirus integration in bladder cancer of kidney transplant recipients reveals mechanisms of the integration at the nucleotide level. <i>Oncogene</i> , 2021, 40, 46-54.	2.6	8
36	Outcomes of older men receiving docetaxel for metastatic hormone-sensitive prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 1181-1188.	2.0	7

#	ARTICLE	IF	CITATIONS
37	Multicancer Early Detection Technologies: A Review Informed by Past Cancer Screening Studies. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 1139-1145.	1.1	7
38	Resolution of a High Grade and Metastatic BK Polyomavirus-Associated Urothelial Cell Carcinoma Following Radical Allograft Nephroureterectomy and Immune Checkpoint Treatment: A Case Report. <i>Transplantation Proceedings</i> , 2020, 52, 2720-2725.	0.3	6
39	The Art of Oncology: COVID-19 Era. <i>Oncologist</i> , 2020, 25, 997-1000.	1.9	6
40	PIK Carefully, AKT Accordingly: Towards Precision Medicine in Prostate Cancer. <i>European Urology</i> , 2020, 78, 845-846.	0.9	1
41	Activity of gemcitabine and vinorelbine in patients with metastatic urothelial carcinoma.. <i>Journal of Clinical Oncology</i> , 2015, 33, e15507-e15507.	0.8	1
42	Integrated comprehensive high-throughput kinomics profiling and whole exome sequencing of penile squamous cell cancer (PSCC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 383-383.	0.8	1
43	Outcomes of older men receiving docetaxel for metastatic hormone-sensitive prostate cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 82-82.	0.8	0
44	Symptom burden, functional status, and clinical outcomes of hospitalized patients with advanced genitourinary cancers.. <i>Journal of Clinical Oncology</i> , 2021, 39, 42-42.	0.8	0
45	Pathologic down-staging and complete pathologic response with gemcitabine and cisplatin neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma of the bladder.. <i>Journal of Clinical Oncology</i> , 2012, 30, 307-307.	0.8	0
46	Chemoradiation for locally advanced penile squamous cell carcinoma (PSCC): A multi-institution retrospective study.. <i>Journal of Clinical Oncology</i> , 2014, 32, e15616-e15616.	0.8	0
47	Renal function in bladder cancer patients after trimodality therapy: Long-term results of a large institutional experience.. <i>Journal of Clinical Oncology</i> , 2016, 34, 453-453.	0.8	0
48	Risk factors for disease progression after post-prostatectomy salvage radiation: Long-term results of a large institutional experience.. <i>Journal of Clinical Oncology</i> , 2016, 34, 110-110.	0.8	0
49	Comprehensive genomic profiling to identify clinically relevant genomic alterations in patients with advanced penile cancers.. <i>Journal of Clinical Oncology</i> , 2016, 34, 4573-4573.	0.8	0
50	Branched chain RNA in situ hybridization for androgen receptor splice variant AR-V7 as a prognostic biomarker for metastatic castration-sensitive prostate cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, e16571-e16571.	0.8	0
51	A phase II, multicenter, single-arm trial of CV301 plus atezolizumab (Atezo) in locally advanced (unresectable) or metastatic urothelial cancer (UC).. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS494-TPS494.	0.8	0
52	Phase 2 trial of CV301 vaccine plus atezolizumab (Atezo) in advanced urothelial carcinoma (aUC).. <i>Journal of Clinical Oncology</i> , 2022, 40, 511-511.	0.8	0